Amgen Inc. is a biopharmaceutical leader focused on molecular biology and biochemistry, with the aim of developing products based on advances in cellular and molecular biology. It operates in one business segment, developing novel human therapeutics for patients with serious illnesses.
Founded in Thousand Oaks, California in 1980, Amgen has grown from a small drug development company into a global biopharmaceutical giant, remaining at the forefront of biotechnology.
Amgen's product portfolio includes treatments for anemia, rheumatoid arthritis, bone diseases, and other serious illnesses. It is known for popular drugs such as Neulasta, Enbrel, and Prolia/Xgeva.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert A. Bradway | Chairman, CEO & President | 5.49M | N/A | 1963 |
| Mr. Peter H. Griffith | Executive VP & CFO | 2.57M | N/A | 1959 |
| Mr. Esteban Santos | Executive Vice President of Operations | 2.52M | N/A | 1968 |
| Dr. David M. Reese M.D. | Executive Vice President of Research & Development | 2.83M | N/A | 1963 |
| Mr. Murdo Gordon | Executive VP of Global Commercial Operations | 2.72M | N/A | 1967 |
| Mr. Matthew C. Busch | Chief Accounting Officer & VP of Finance | N/A | N/A | 1974 |
| Mr. Mike Zahigian | Senior VP & Chief Information Officer | N/A | N/A | N/A |
| Mr. Arvind Sood | Vice President of Investor Relations | N/A | N/A | N/A |
| Mr. Jonathan P. Graham | Executive VP, General Counsel & Secretary | 2.44M | N/A | 1961 |
| Ms. Nancy A. Grygiel | Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer | N/A | N/A | 1968 |
Charts and financial information provided by TradingView, a popular charting & trading platform.
Check out even more advanced features or grab charts for your website.
This post has been viewed 4 times.
